Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Aug;115(7):1253–1259. doi: 10.1111/j.1476-5381.1995.tb15033.x

Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline.

S Appel 1, R A Mathôt 1, M W Langemeijer 1, A P IJzerman 1, M Danhof 1
PMCID: PMC1908771  PMID: 7582553

Abstract

1. The purpose of this investigation was to develop a pharmacokinetic-pharmacodynamic model for the interaction between an adenosine A1 receptor agonist and antagonist in vivo. The adenosine A1 receptor agonist, N6-cyclopentyladenosine (CPA) and the antagonist, 8-cyclopentyltheophylline (CPT) were used as model drugs. The CPA-induced reduction in mean arterial pressure and heart rate were used as measurements of effect. 2. Four groups of eight rats each received 200 micrograms kg-1 of CPA i.v. in 5 min during a steady-state infusion of CPT at a rate of 0, 57, 114 or 228 micrograms kg-1 h-1. The haemodynamic parameters were continuously measured and frequent blood samples were taken to determine the pharmacokinetics of the drugs. 3. CPT had no influence on the pharmacokinetics of CPA and the baseline values of the haemodynamic variables. Furthermore, no clear antagonism by CPT was observed of the CPA-induced reduction in mean arterial pressure. However, CPT antagonized the effect on heart rate, and with increasing CPT concentrations, a parallel shift of the CPA concentration-effect relationship to the right was observed. 4. An agonist-antagonist interaction model was used to characterize the interaction quantitatively. On the basis of this model, the pharmacodynamic parameters of both CPA and CPT could be estimated. For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1. 5.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1253

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belardinelli L., Fenton R. A., West A., Linden J., Althaus J. S., Berne R. M. Extracellular action of adenosine and the antagonism by aminophylline on the atrioventricular conduction of isolated perfused guinea pig and rat hearts. Circ Res. 1982 Nov;51(5):569–579. doi: 10.1161/01.res.51.5.569. [DOI] [PubMed] [Google Scholar]
  2. Belardinelli L., Lerman B. B. Adenosine: cardiac electrophysiology. Pacing Clin Electrophysiol. 1991 Nov;14(11 Pt 1):1672–1680. doi: 10.1111/j.1540-8159.1991.tb02742.x. [DOI] [PubMed] [Google Scholar]
  3. Bruns R. F., Fergus J. H., Badger E. W., Bristol J. A., Santay L. A., Hartman J. D., Hays S. J., Huang C. C. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):59–63. doi: 10.1007/BF00165037. [DOI] [PubMed] [Google Scholar]
  4. Daly J. W. Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197–207. doi: 10.1021/jm00345a001. [DOI] [PubMed] [Google Scholar]
  5. Daval J. L., Nehlig A., Nicolas F. Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci. 1991;49(20):1435–1453. doi: 10.1016/0024-3205(91)90043-b. [DOI] [PubMed] [Google Scholar]
  6. Dingemanse J., Danhof M., Breimer D. D. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther. 1988;38(1):1–52. doi: 10.1016/0163-7258(88)90101-5. [DOI] [PubMed] [Google Scholar]
  7. Evans D. B., Schenden J. A., Bristol J. A. Adenosine receptors mediating cardiac depression. Life Sci. 1982 Nov 29;31(22):2425–2432. doi: 10.1016/0024-3205(82)90746-9. [DOI] [PubMed] [Google Scholar]
  8. Holford N. H., Sheiner L. B. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16(2):143–166. doi: 10.1016/0163-7258(82)90051-1. [DOI] [PubMed] [Google Scholar]
  9. Holford N. H., Sheiner L. B. Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng. 1981;5(4):273–322. [PubMed] [Google Scholar]
  10. Hutchison A. J., Webb R. L., Oei H. H., Ghai G. R., Zimmerman M. B., Williams M. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther. 1989 Oct;251(1):47–55. [PubMed] [Google Scholar]
  11. Jonkers R., van Boxtel C. J., Koopmans R. P., Oosterhuis B. A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. J Pharmacol Exp Ther. 1989 Apr;249(1):297–302. [PubMed] [Google Scholar]
  12. Kusachi S., Thompson R. D., Olsson R. A. Ligand selectivity of dog coronary adenosine receptor resembles that of adenylate cyclase stimulatory (Ra) receptors. J Pharmacol Exp Ther. 1983 Nov;227(2):316–321. [PubMed] [Google Scholar]
  13. Londos C., Cooper D. M., Wolff J. Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A. 1980 May;77(5):2551–2554. doi: 10.1073/pnas.77.5.2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mandema J. W., Tukker E., Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther. 1992 Jan;260(1):36–44. [PubMed] [Google Scholar]
  15. Martens D., Lohse M. J., Rauch B., Schwabe U. Pharmacological characterization of A1 adenosine receptors in isolated rat ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Sep;336(3):342–348. doi: 10.1007/BF00172688. [DOI] [PubMed] [Google Scholar]
  16. Mathôt R. A., Appel S., van Schaick E. A., Soudijn W., IJzerman A. P., Danhof M. High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. J Chromatogr. 1993 Oct 22;620(1):113–120. doi: 10.1016/0378-4347(93)80058-c. [DOI] [PubMed] [Google Scholar]
  17. Mathôt R. A., van Schaick E. A., Langemeijer M. W., Soudijn W., Breimer D. D., Ijzerman A. P., Danhof M. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther. 1994 Feb;268(2):616–624. [PubMed] [Google Scholar]
  18. Oei H. H., Ghai G. R., Zoganas H. C., Stone G. A., Zimmerman M. B., Field F. P., Williams M. Correlation between binding affinities for brain A1 and A2 receptors of adenosine agonists and antagonists and their effects on heart rate and coronary vascular tone. J Pharmacol Exp Ther. 1988 Dec;247(3):882–888. [PubMed] [Google Scholar]
  19. Spielman W. S., Thompson C. I. A proposed role for adenosine in the regulation of renal hemodynamics and renin release. Am J Physiol. 1982 May;242(5):F423–F435. doi: 10.1152/ajprenal.1982.242.5.F423. [DOI] [PubMed] [Google Scholar]
  20. Tang-Liu D. D., Tozer T. N., Riegelman S. Urine flow-dependence of theophylline renal clearance in man. J Pharmacokinet Biopharm. 1982 Aug;10(4):351–364. doi: 10.1007/BF01065168. [DOI] [PubMed] [Google Scholar]
  21. Trivedi B. K., Blankley C. J., Bristol J. A., Hamilton H. W., Patt W. C., Kramer W. J., Johnson S. A., Bruns R. F., Cohen D. M., Ryan M. J. N6-substituted adenosine receptor agonists: potential antihypertensive agents. J Med Chem. 1991 Mar;34(3):1043–1049. doi: 10.1021/jm00107a025. [DOI] [PubMed] [Google Scholar]
  22. Ueeda M., Thompson R. D., Padgett W. L., Secunda S., Daly J. W., Olsson R. A. Cardiovascular actions of adenosines, but not adenosine receptors, differ in rat and guinea pig. Life Sci. 1991;49(18):1351–1358. doi: 10.1016/0024-3205(91)90199-l. [DOI] [PubMed] [Google Scholar]
  23. Webb R. L., McNeal R. B., Jr, Barclay B. W., Yasay G. D. Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat. J Pharmacol Exp Ther. 1990 Sep;254(3):1090–1099. [PubMed] [Google Scholar]
  24. Williams M., Braunwalder A., Erickson T. J. Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue. Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):179–183. doi: 10.1007/BF00511410. [DOI] [PubMed] [Google Scholar]
  25. van Calker D., Müller M., Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem. 1979 Nov;33(5):999–1005. doi: 10.1111/j.1471-4159.1979.tb05236.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES